Inhibidores SGLT2 Al igual que los iDPP4, este grupo farmacolgico no se ha asociado o tiene una asociacin mnima con efectos adversos gastrointestinales
Aja S, Landree LE, Kleman AM, Medghalchi SM, Vadlamudi A, McFadden JM, Aplasca A, Hyun J, Plummer E, Daniels K, Kemm M, Townsend CA, Thupari JN, Kuhajda FP, Moran TH, Ronnett GV: Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight
Autophagy-lysosomal pathway impairment induces molecular signatures, including elevated LC3-II expression with concomitant LC3-II/LC3-I ratio upregulation, p62 accumulation and reduced histone D levels (125)
Kindle Edition Published March 4, 2025 About the author Ratings & Reviews Friends & Following Community Reviews Displaying 1 - 2 of 2 reviews Author 1 book March 25, 2025 Discovering the Real Benefits of GLP-1 Medications This insightful guide completely transformed my understanding of GLP-1 medications and their impact on weight loss
Tardif, J
Its development represents a significant area of interest in obesity pharmacotherapy, particularly given the limitations of existing treatments in achieving sustained, substantial weight reduction in all patient groups
